Recipients of granulocyte-colony stimulating factor/granulocyte macrophage-colony stimulating factor are not only individuals with underlying disorders, but also healthy donors undergoing peripheral blood progenitor cell (PBPC) mobilization. In addition to the known adverse effects associated with G-CSF, complications such as splenic rupture have also been reported. A review of the English literature, with addition of a patient with plasma cell myeloma, reveals that splenic rupture occurs not only in patients with underlying disease, but also in healthy PBPC donors. Although the cause of splenic rupture does not appear to be associated with any specific condition, physicians should be alerted to the possibility of this potentially fatal complication in individuals receiving G-CSF therapy.
Introduction
Granulocyte-colony stimulating factor (G-CSF) and granulocyte macrophage-colony stimulating factor (GM-CSF) are glycoproteins that mediate production and differentiation of granulocytes and macrophages. G-CSF is used to improve granulocyte counts in patients with chronic neutropenia due to chemotherapy or myelodysplastic syndrome or to mobilize peripheral blood progenitor cells (PBPC) for stem cell transplantation as well as to reconstitute the bone marrow following stem cell transplant. The recipients of G-CSF are not only individuals with underlying disorders, but also healthy donors undergoing PBPC mobilization. Many adverse effects have been associated with G-CSF use, including generalized symptoms such as fatigue, headache, bone pain, musculoskeletal pain, nausea, insomnia and skin rash. 1 Serious complications such as splenic rupture have also been reported. We present a patient from our institution with plasma cell myeloma (multiple myeloma), who experienced splenic rupture during PBPC mobilization. The salient features of all cases with splenic rupture involving G-CSF/GM-CSF treatment that have been reported in the English literature are summarized in Table 1 . [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] The cases include individuals receiving G-CSF/GM-CSF for neutropenia, patients being prepared for autologous stem cell transplant and donors undergoing PBPC mobilization. Of note is the fact that spontaneous splenic ruptures occurred not only in diseased patients, but also in healthy donors.
Case report
The patient is a 53-year-old man with a past medical history of asthma, hypercholesterolemia and plasma cell myeloma diagnosed in October 2000 with chronic renal insufficiency secondary to light chain disease. He also had transfusion-dependent anemia and coagulopathy secondary to an unknown circulating inhibitor. There was no family history of bleeding disorders or hematological malignancies. He was treated with four cycles of VAD beginning November 2000. In February 2001, the patient was given a dose of cyclophosphamide 4.5 g/m 2 and on day 5, GM-CSF was added at 5 mg/kg/day. On the 10th day he was admitted for neutropenic fever, worsening renal failure and hypotension with a temperature of 101.31F and blood pressure of 90/52 mm Hg. He was treated with intravenous piperacillin/tazobactum and levofloxacin and was started on a dobutamine drip. He also received a single dose of GM-CSF on the day of admission. On the second day of admission, G-CSF at 10 mg/kg/day was added to the treatment regimen and GM-CSF at 5 mg/kg/day was continued. Leukapheresis was performed from day 7 to 10, after the initial growth factor administration. Two days after leukapheresis, the patient started to complain of cough, malaise, vague abdominal discomfort and pain radiating to the left shoulder. The blood pressure was 90/ 54 mm Hg. His WBC and hemoglobin showed a marked /l and hemoglobin from 9.7 to 7.7 g/dl, respectively. After 2 U of packed red blood cells the hemoglobin was 7.9 g/dl. A noncontrast computed tomography (CT) of the abdomen and pelvis revealed a ruptured/lacerated spleen with hemoperitoneum and pelvic ascites. The patient underwent an emergency splenectomy with additional transfusion of 4 U of packed red blood cells.
The
Pathology. The spleen measured 14 Â 11.5 Â 5.2 cm and weighed 354 g. On the external surface, it showed adherent blood clots and multiple subcapsular hematomas, containing clotted blood, the largest of which was 5.0 Â 4.0 Â 0.8 cm. The splenic parenchyma was dark red, soft and otherwise unremarkable. Microscopic examination showed markedly thinned capsule covering these hematomas and in some areas the capsule was only a few cell layers thick. The splenic sinuses were filled with predominantly granulocytic precursors in all stages of maturation with an admixture of some erythroid precursors and megakaryocytes, indicative of extramedullary hematopoiesis. The red pulp cords showed an abundant infiltrate comprised almost exclusively of granulocytic precursors also in all stages of maturation.
Immunohistochemistry. A myeloperoxidase immunostain showed focal areas of capsular infiltration by the granulocytic precursors, most notably in the areas of marked capsular thinning. It further highlighted the overwhelming predominance of granulocytic precursors within the sinusoids of the red pulp. The splenic macrophages also revealed myeloperoxidase positivity secondary to engulfed granulocytes. The numerous macrophages were further highlighted by both CD68 and lysozyme.
Due to the patient's history of multiple myeloma, k-and l-immunostains were obtained, which did not reveal any obvious clonal population. Immunostaining with CD3 and CD20 revealed the white pulp to contain appropriate numbers of T and B cells. Factor VIII showed usual positivity for the megakaryocyte cytoplasm. Hemoglobin A positivity in the clusters of erythroid precursors further confirmed the presence of extramedullary hematopoiesis. Tissue Gram stains obtained to evaluate for the possibility of sepsis were negative for organisms.
Discussion
In addition to the well known adverse effects of G-CSF therapy, splenomegaly is increasingly being noted as a common finding. Many prospective studies examining the relationship between G-CSF administration, including dosage and duration and the changes in spleen size from baseline to during and after G-CSF therapy are published. In a study by Platzbecker et al., 14 spleen size in 91 healthy donors receiving G-CSF (7.5 mg/kg/day) for 5 days was assessed. An increase in spleen size after completion of the G-CSF therapy as compared to baseline size was noted with a mean increase in length of 1.1 cm. Two published studies by Stroncek et al. 15 examined changes in spleen size at a higher G-CSF dose of 10 mg/kg/day for 5 days. One study showed an increase in spleen size with a mean increase in length of 1.5 cm in 19 out of 20 donors. A return to baseline size was observed after 3-4 days after apheresis. 15 The second study followed 18 donors and showed an increase in spleen size on the day of apheresis from baseline size in 17 out of 18 donors with a mean increase of 1.4 cm. A follow up ultrasound on day 10-11 showed a return to baseline size in most individuals. 16 The splenomegaly has been attributed to infiltration of the red pulp by granulocytes in some cases as well as the presence of extramedullary hematopoiesis in others. Although splenomegaly seems to be a common side effect, there are only occasional cases of splenic rupture reported and we have attempted to identify all cases of splenic rupture related to G-CSF/GM-CSF therapy reported in the English literature (Table 1) 2-13 with an additional case from our institution. Recently, a similar study was published by Nuamah et al., 12 but it does not include all published cases. We have identified 15 cases of which 5 were donors, 6 were patients being prepared for autologous stem cell transplantation (AutoSCT), 3 were patients with cytopenias and 1 was a patient undergoing cytotoxic enhancement for AML. The five donors were between 22-51 years of age and included four men and one woman. The auto-SCT patients were four women and two men with an age range between 22-59 years. The three patients with cytopenias included two men and one woman between the ages of 38-51 years. The patient with AML undergoing cytotoxic enhancement was a 56-year-old woman. As noted in Table 1 , there is a broad range of underlying disorders with most being hematologic.
2-13
The splenic rupture occurred not only in patients with underlying hematopoietic disorders, but also in patients with solid tumors and healthy donors. Most patients experienced malaise, pain radiating to the left shoulder, drop in blood pressure and decrease in hematocrit. In six cases, splenic rupture occurred between day 5 to day 10 after initiation of G-CSF therapy, 2,4,5,10,12,13 but in three cases, it occurred as early as day 2 and 3. 7, 8, 11 In four of the cases (including our case), the rupture occurred 1-3 days following leukapheresis. 3, 6, 9 In two of the three cases of amyloidosis, splenic rupture occurred as late as day 17 and 20, respectively, after stem cell transfusion; however, the enlargement of the spleen due to amyloid deposition may have been a contributing factor. 8 The splenic weight, compared with normal splenic weights of 100-150 g, appears to increase up to threefold. Although there is an increase in the size of the spleen in most cases, some of the cases did not have significant splenomegaly. Unfortunately a baseline splenic size is not available for comparison in these cases. Only one case, that of a donor, stands out with a splenic weight of 945 g. 3 Hence, weight does not appear to be an isolated factor for cause of rupture. Coagulopathy has been alluded to as a possible causative agent, which was also recorded in our patient; however it is unlikely to be the sole cause. The presence of benign immunoblastic infiltrates could quite possibly act as a synergistic factor together with granulocytic precursor infiltrates. Splenic rupture is known and reported in infectious mononucleosis, when immunoblastic infiltrates completely efface the splenic architecture and the spleen size can reach up to 970 g. 17 In the present case, there was very obvious and striking evidence of thinned out capsule by the granulocytic infiltrates, which yielded to increased pressure resulting in leakage of blood into the peritoneal cavity.
Another factor to be considered as a possible etiology is underlying disorders such as infiltration by amyloid 8 or an abnormal myeloid infiltrate. 4, 7, 11 However, this does not explain the cause of rupture in healthy donors. A probable cause or risk factor of rupture is not apparent from studying a limited number of cases or from the data available. Two of the 15 cases described in Table 1 (approximately 13%) resulted in death due to splenic rupture. 1, 6 Unfortunately, these patients did not undergo emergency splenectomies. With the increasing use of G-CSF, it is important to be aware of this potentially fatal complication and to educate both clinicians and patients to watch out for signs and symptoms that might be a clue to possible splenic rupture. Prospective studies that include details of the health status, baseline spleen size, CBC and follow-up of individuals receiving G-CSF may be required to attempt and identify definite risk factors for rupture to prevent fatal complications.
